Sanofi Pasteur Acquires Protein Sciences

Sanofi Pasteur has acquired Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Conn. Protein Sciences received U.S. Food and Drug Administration approval in October 2016 for its Flublok quadrivalent influenza vaccine, the only recombinant protein-based influenza vaccine. The acquisition will allow Sanofi to broaden its flu portfolio. “Protein Sciences was actively looking for an opportunity to grow its business, particularly in the U.S.,” said Manon M.J. Cox, president and chief executive officer of Protein Sciences. “As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur’s expertise in the field of influenza vaccines.”